Format

Send to

Choose Destination
J Am Acad Dermatol. 2011 Aug;65(2):389-403. doi: 10.1016/j.jaad.2010.04.026. Epub 2010 Jun 26.

Tyrosine kinases in inflammatory dermatologic disease.

Author information

1
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Geriatric Research Education and Clinical Center, Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, California.
2
Department of Dermatology, Stanford University School of Medicine, Stanford, California.
3
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Geriatric Research Education and Clinical Center, Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, California. Electronic address: wrobins@stanford.edu.

Abstract

Tyrosine kinases (TKs) are enzymes that catalyze the phosphorylation of tyrosine residues on protein substrates. They are key components of signaling pathways that drive an array of cellular responses including proliferation, differentiation, migration, and survival. Specific TKs have recently been identified as critical to the pathogenesis of several autoimmune and inflammatory diseases. Small-molecule inhibitors of TKs are emerging as a novel class of therapy that may provide benefit in certain patient subsets. In this review, we highlight TK signaling implicated in inflammatory dermatologic diseases, evaluate strategies aimed at inhibiting these aberrant signaling pathways, and discuss prospects for future drug development.

PMID:
20584561
PMCID:
PMC2948077
DOI:
10.1016/j.jaad.2010.04.026
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center